Unknown PHASE3 INTERVENTIONAL 2-arm NCT04603508

Efficacy and Safety of Berlim 25/10 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia

National, Multicenter, Randomized, Double-blind, Triple-dummy, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Berlim 25/10 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia.

Sponsor: EMS

Conditions Dyslipidemia Type 2 Diabetes Mellitus

Interventions BERLIM 25/10 ASSOCIATION PLACEBO BERLIM 25/10 association EMPAGLIFLOZIN EMPAGLIFLOZIN PLACEBO ROSUVASTATIN CALCIUM ROSUVASTATIN CALCIUM PLACEBO

Updated 6 times since 2020 Last updated: Aug 3, 2022 Started: Mar 31, 2023 Primary completion: Apr 30, 2025 Completion: Aug 31, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04603508, this PHASE3 trial focuses on Dyslipidemia and Type 2 Diabetes Mellitus and remains ongoing. Sponsored by EMS, it has been updated 6 times since 2023, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Oct 2025 — Present [monthly]

Unknown PHASE3

Status: Not Yet Recruiting → Unknown
Sep 2024 — Oct 2025 [monthly]

Not Yet Recruiting PHASE3
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE3
Sep 2022 — Jul 2024 [monthly]

Not Yet Recruiting PHASE3
Jan 2021 — Sep 2022 [monthly]

Not Yet Recruiting PHASE3

▶ Show 1 earlier version

Nov 2020 — Jan 2021 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Data source: EMS

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.